InterMune enrolls 600th patient in phase III Actimmune trial

By E. Janene Geiss

Philadelphia, Nov. 9 - InterMune, Inc. InterMune, Inc. announced Wednesday that it has enrolled the 600th patient in its pivotal phase III Inspire clinical trial almost two months ahead of schedule.

The randomized, double-blind, placebo-controlled Inspire trial, designed to determine if Actimmune (interferon gamma-1b) decreases mortality in patients with idiopathic pulmonary fibrosis, is scheduled to conclude near the end of 2007, officials said in a company news release.

Last month, InterMune announced that it would enroll an additional 200 patients in the trial to increase the likelihood of observing the planned number of total events prior to the time the trial is scheduled to conclude.

Since the end of the trial is tied to the enrollment of the 600th patient, the additional 200 patients will not increase the trial duration, officials said.

InterMune anticipates enrollment of the 800th patient in the first half of 2006. The trial is currently enrolling at 80 sites in North America and Europe, officials said.

InterMune is a Brisbane, Calif.-based biopharmaceutical company focused on the development of therapies in pulmonology and hepatology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.